T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.18% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Apogee Enterprises
APOG
$897M
| $1.2M | ﹤0.01% |
30,469
-19
| -0.1% | -$813 |
|
1802
DNOW Inc
DNOW
$3.04B
| $1.2M | ﹤0.01% |
122,212
-19,058
| -13% | -$203K |
|
1803
Liberty Global Class A
LBTYA
$3.55B
| $1.19M | ﹤0.01% |
56,729
+1,400
| +3% | +$32.9K |
|
1804
Tronox
TROX
$958M
| $1.19M | ﹤0.01% |
70,955
-9,976
| -12% | -$181K |
|
|
AVTA
1805
DELISTED
Avantax, Inc. Common Stock
AVTA
| $1.19M | ﹤0.01% |
64,518
-2,181
| -3% | -$39.7K |
|
1806
Greif
GEF
$5.03B
| $1.18M | ﹤0.01% |
18,973
+540
| +3% | +$33K |
|
1807
NIO
NIO
$11.3B
| $1.18M | ﹤0.01% |
54,500
| – | – |
|
1808
First Interstate BancSystem
FIBK
$3.7B
| $1.18M | ﹤0.01% |
30,890
+1,146
| +4% | +$40.9K |
|
1809
Glaukos
GKOS
$11.2B
| $1.18M | ﹤0.01% |
25,891
+1,119
| +5% | +$53.1K |
|
1810
Federated Hermes
FHI
$4.7B
| $1.18M | ﹤0.01% |
36,976
+48
| +0.1% | +$1.52K |
|
1811
Energizer
ENR
$1.55B
| $1.17M | ﹤0.01% |
41,302
+2,377
| +6% | +$71.5K |
|
|
B
1812
DELISTED
Barnes Group Inc.
B
| $1.17M | ﹤0.01% |
37,606
+1,142
| +3% | +$39.8K |
|
1813
Federal Agricultural Mortgage
AGM
$2.58B
| $1.17M | ﹤0.01% |
11,965
+56
| +0.5% | +$5.76K |
|
1814
Atlantic Union Bankshares
AUB
$6.09B
| $1.17M | ﹤0.01% |
34,361
+360
| +1% | +$12.5K |
|
1815
Sensient Technologies
SXT
$5.53B
| $1.16M | ﹤0.01% |
14,424
-348
| -2% | -$28.9K |
|
1816
Evolent Health
EVH
$527M
| $1.16M | ﹤0.01% |
37,759
+3,382
| +10% | +$98.6K |
|
1817
CytomX Therapeutics
CTMX
$730M
| $1.16M | ﹤0.01% |
633,418
-27,645
| -4% | -$52.9K |
|
1818
The Honest Company
HNST
$540M
| $1.16M | ﹤0.01% |
396,432
-69,141
| -15% | -$250K |
|
|
AGR
1819
DELISTED
Avangrid, Inc.
AGR
| $1.16M | ﹤0.01% |
25,085
+4,724
| +23% | +$219K |
|
|
MZTI
1820
The Marzetti Company
MZTI
$3.22B
| $1.15M | ﹤0.01% |
8,916
+558
| +7% | +$76.4K |
|
1821
Evercore
EVR
$12B
| $1.14M | ﹤0.01% |
12,202
-345
| -3% | -$36.8K |
|
1822
Sanmina
SANM
$11.2B
| $1.14M | ﹤0.01% |
27,981
+170
| +0.6% | +$7.03K |
|
1823
Lakeland Financial Corp
LKFN
$1.55B
| $1.14M | ﹤0.01% |
17,152
+184
| +1% | +$13.1K |
|
1824
Appian
APPN
$2.65B
| $1.14M | ﹤0.01% |
24,007
+769
| +3% | +$38.7K |
|
|
NFNT.U
1825
DELISTED
Infinite Acquisition Corp. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant
NFNT.U
| $1.13M | ﹤0.01% |
114,000
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.